TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03435250
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel, IV, once during each 21-day cycle, until disease progression or unacceptable toxicity.
Study: NCT03435250
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study: NCT03435250
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine, IV, on Days 1, 8, and 15 of each 28-day cycle, until disease progression or unacceptable toxicity.
Study: NCT02415608
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given orally in 28-day cycles
Study: NCT02241616
Drug: Entecavir+Fuzheng Huayu+TCM Granule
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
Study: NCT00272584
Drug: Risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01499940
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
Study: NCT02080715
Drug: Tolcapone
Normalized name: Tolcapone
DrugBank: Tolcapone (DB00323)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
Study: NCT00634933
Drug: TRU-015
Normalized name: TRU-015
DrugBank: TRU-015 (DB05580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
Study: NCT00634933
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
Study: NCT00634933
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
Study: NCT00634933
Drug: TRU-015
Normalized name: TRU-015
DrugBank: TRU-015 (DB05580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
Study: NCT00634933
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
Study: NCT00634933
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
Study: NCT00634933
Drug: TRU-015
Normalized name: TRU-015
DrugBank: TRU-015 (DB05580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
Study: NCT00634933
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
Study: NCT04109547
Drug: Oral semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets to be taken once-daily for 26 weeks
Study: NCT01550003
Drug: Certolizumab Pegol (CZP)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Reduced CZP regimen (after implementation of protocol amendments 4 and 5):~* 10 to \< 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* ≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);
Study: NCT01550003
Drug: Certolizumab Pegol (CZP)
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.~CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.~Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range.~Original CZP regimen (prior to implementation of protocol amendments 4 and 5 and after implementation of protocol amendment 9):~* 10 to \< 20 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);~* 20 to \< 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc,); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);~* ≥ 40 kg: Loading dose = 400 mg Q2W (2 x 1.0 mL sc); treatment dose = 200 mg Q2W (1 x 1.0 mL sc);
Study: NCT04218240
Drug: Pregabalin 200 MG capsules
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral pregabalin 200 mg capsules given with a taper on day 5
Study: NCT04218240
Drug: Lofexidine 0.18Mg Tab
Normalized name: LOFEXIDINE 0.18MG TAB
DrugBank: Lofexidine (DB04948)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lofexidine 0.18 tab given with a taper starting on day 5
Study: NCT04476862
Drug: Cerliponase Alfa
Normalized name: Cerliponase alfa
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Commercially available product provided to patient by participating clinic site.
Study: NCT00634933
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
Study: NCT01509651
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
Study: NCT03547219
Drug: Escitalopram
Normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00906516
Drug: Neuradiab in combination with Bevacizumab (Avastin)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.~Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient.
Study: NCT02839096
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
Study: NCT01436149
Drug: SPD489 (Lisdexamfetamine dimesylate )
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Study: NCT02698215
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily
Study: NCT02698215
Drug: Varenicline plus Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
Study: NCT00573508
Drug: Solifenacin Succinate
Normalized name: Solifenacin Succinate
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Administration
Study: NCT04603846
Drug: anti-PD-L1 antibody
Normalized name: Protease-activated anti-pd-l1 antibody prodrug cx-072
DrugBank: Pacmilimab (DB18873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.
Study: NCT04603846
Drug: albumin bound paclitaxel
Normalized name: Albumin bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive 6 cycles of albumin bound paclitaxel 260mg/m2 on days 1 every 3 weeks .
Study: NCT03860870
Drug: Clenbuterol Oral Product
Normalized name: clenbuterol Oral Product
DrugBank: Clenbuterol (DB01407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects ingest 4x20 microgram clenbuterol tablets
Study: NCT03879811
Drug: TMZ
Normalized name: TMZ
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral TMZ at 150mg/m2
Study: NCT03879811
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab via IV infusion at 480 mg every four weeks (Q4W) starting 4 weeks after TMZ day 1
Study: NCT01030731
Drug: Ceftobiprole
Normalized name: Ceftobiprole
DrugBank: Ceftobiprole (DB04918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftobiprole 250mg single dose over 2 hours.
Study: NCT02183948
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02079896
Drug: Lexaptepid pegol (NOX-H94)
Normalized name: Certolizumab Pegol
DrugBank: Lexaptepid pegol (DB12578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: anti-hepcidin L-RNA-aptamer (Spiegelmer)
Study: NCT01508221
Drug: Trental
Normalized name: Trental
DrugBank: Pentoxifylline (DB00806)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
Study: NCT04351334
Drug: Alectinib
Normalized name: Alectinib
DrugBank: Alectinib (DB11363)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observational treatment based on physician choice
Study: NCT03812731
Drug: Ropivacaine
Normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperatively after induction of anaesthesia caudal epidural block will be administered with 0.2% ropivacaine 1-ml/kg
Study: NCT01186289
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
Study: NCT00334893
Drug: eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given IV
Study: NCT02575963
Drug: Cytarabine (Phase 1 only)
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
Study: NCT02575963
Drug: Furosemide (Phase 1 only)
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
Study: NCT02330406
Drug: Anagliptin
Normalized name: Anagliptin
DrugBank: Anagliptin (DB12417)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Suiny 100 mg
Study: NCT02330406
Drug: Sitagliptin
Normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Januvia 50 mg Glactiv 50 mg
Study: NCT04004234
Drug: Manganese Chloride
Normalized name: Manganese Chloride
DrugBank: Manganese citrate (DB14495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered by inhalation at 0.2 or 0.4mg/kg/d once daily in a 3-week cycle
Study: NCT04004234
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered intravenously, 125mg/m2/d on day1 and day8 in a 3-week cycle
Study: NCT04004234
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously, 1g/m2/d on day1 and day8 in a 3-week cycle
Study: NCT04004234
Drug: anti-PD-1 antibody
Normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered intravenously, 2-4mg/kg on day 3 in a 3-week cycle
Study: NCT00129246
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
Study: NCT00129246
Drug: Bupropion
Normalized name: Bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
Study: NCT03023124
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment with trabectedin repeated every 21 days for 6 cycles
Study: NCT03023124
Drug: Adriamycin
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Adriamycin at day 1 every 21 days for 6 cycles
Study: NCT03023124
Drug: Dacarbazine
Normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
Study: NCT02184312
Drug: Nevirapine XR low dose
Normalized name: nevirapine Extended Release Oral Tablet
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02184312
Drug: Nevirapine XR medium dose
Normalized name: nevirapine Extended Release Oral Tablet
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02184312
Drug: Nevirapine XR high dose
Normalized name: nevirapine Extended Release Oral Tablet
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02184312
Drug: Nevirapine (VIRAMUNE®)
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01016912
Drug: BMS-790052
Normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 10 mg, daily, 24-48 weeks
Study: NCT01016912
Drug: BMS-790052
Normalized name: BMS-790052
DrugBank: Daclatasvir (DB09102)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 60 mg, daily, 24-48 weeks
Study: NCT01016912
Drug: Peginterferon alfa-2b
Normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
Study: NCT01016912
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
Study: NCT01542047
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
Study: NCT01542047
Drug: Pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
Study: NCT03372304
Drug: Ropivacaine 0.2%
Normalized name: ROPivacaine 0.2% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perineural infusion of Ropivacaine 0.2% using a peripheral nerve block catheter and a portable infusion pump.
Study: NCT02596074
Drug: Omiganan (CLS001) topical gel
Normalized name: Omiganan
DrugBank: Omiganan (DB06610)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02596074
Drug: Vehicle topical gel
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01503866
Drug: bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, single dose
Study: NCT00732056
Drug: GRN163L
Normalized name: Grn163l
DrugBank: Grn163l (DB05036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25% dose escalation infused over 2 hours weekly
Study: NCT01288911
Drug: enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: capsules
Study: NCT01288911
Drug: bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablets
Study: NCT02680249
Drug: CTP-656
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT03258710
Drug: Tenofovir Disoproxil Fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
Study: NCT00863265
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will undergo three diet periods of 21 days each separated by 7 day washouts. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. During each period subjects will receive either phytosterol esters or placebo and ezetimibe or placebo.
Study: NCT05342870
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Following a sequential allocation scheme, the dexmedetomidine dose for each patient was determined by the Dixon up-and-down method. The dexmedetomidine dose for the first patient was 0.5 µg/kg. The dose was then adjusted in 0.1 µg/kg increments for the following patients depending on the success of the previous patient's block. If a patient experienced tourniquet pain prior to T0 + 50 minutes the next patient received a higher dose. If a patient did not experience pain at T0 + 50 minutes of tourniquet time the dose for the following patient was decreased. Identical syringes containing the solution mix were prepared by the principal investigator and handed to the blinded anesthesiologist in the room. Stopping rules were set at 6 independent crossovers in the same direction (no pain to pain or pain to no pain), with a minimum number of 20 patients
Study: NCT00284947
Drug: basiliximab
Normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 40 mg once every 28 days intravenously for 24 weeks
Study: NCT00121251
Drug: Gemcitabine Hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00121251
Drug: Sorafenib Tosylate
Normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02158442
Drug: Timentin
Normalized name: Timentin
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The Control Group will receive standard dosings of intravenous Timentin plus other standard care.